Project Grant R21CA284153
Award Date 7/8/24
Completion Date 6/30/26
Dollars Obligated $402K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
- This $652,751 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research focused on engineering antibody drug conjugates (ADCs) to enhance the therapeutic window for treating glioblastoma (GBM) and other central nervous system cancers. The award to Mayo Clinic, a renowned academic medical center, aims to leverage recent findings...
- The Project Grant award titled "Using Germline and Somatic Genetics to Elucidate Glioma Risk and Improve Patient Outcomes" was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) beginning in 2016 and expanding in 2021. The $484,803 award supports research to evaluate the genetic predisposition of developing brain tumors with clinically relevant acquired alterations or high mutation burdens, and to determine the clinical utility of germline...
- The National Cancer Institute (NCI) awarded a $404,972 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Texas Health Science Center at San Antonio (UTHSCSA) to conduct research on ribosome biogenesis and modifications in glioblastoma (GBM). The 2-year award, starting on August 1, 2025, will focus on identifying differences in small nucleolar RNA (snoRNA) expression and rRNA 2'O methylation profiles between glioma stem cells, astrocytes, and neuronal...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $639,004 to Mayo Clinic from January 1, 2025 to December 31, 2029 to conduct research on using a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key products and services to be delivered under this award include: Collecting and processing pre- and post-treatment tumor tissue and peripheral blood samples...
- The National Cancer Institute awarded a $1,882,680 Project Grant to Duke University to conduct research aimed at "INTEGRATING GENOME-WIDE ASSOCIATION STUDY DATA WITH SINGLE-CELL `OMICS' TO REVEAL THE CELLULAR EFFECTORS OF GLIOBLASTOMA PREDISPOSITION." This grant, funded under the Cancer Biology Research program (CFDA 93.396), supports innovative scientific research to advance the understanding of the fundamental biological mechanisms of glioblastoma, the most common and lethal type...
- This federal Project Grant award of $638,697 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of the SMARCA5 gene in glioblastoma, an incurable brain tumor. The grant recipient, the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, is using the funding to develop a first-in-class, brain-penetrant...
- This $136,412 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant is being used by the Regents of the University of Michigan to fund research aimed at defining how glioblastoma (GBM), the most common and aggressive type of primary brain cancer, acquires and utilizes key metabolites from the brain environment to support tumor growth...
- This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells. The goal is to develop novel therapies for this deadly disease. The research aims to identify GBM patient subsets that will benefit from Notch pathway inhibition or Akt...
- This $412,429 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by Mayo Clinic to investigate new combination drug therapies for high-grade serous ovarian cancer. The research aims to develop approaches to evaluate drug-induced replication stress as a means of identifying novel drug combinations, with a focus on improving outcomes for patients with PARP inhibitor-resistant or recurrent tumors. The project will...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...